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Abstract
Objectives To demonstrate non-inferiority of iobitridol 350
for coronary CT angiography (CTA) compared to higher
iodine content contrast media regarding rate of patients
evaluable for the presence of coronary artery stenoses.
Methods In this multicentre trial, 452 patients were randomized
to receive iobitridol 350, iopromide 370 or iomeprol 400 and
underwent coronary CTA using CT systems with 64-
detector rows or more. Two core lab readers assessed 18
coronary segments per patient regarding image quality
(score 0 = non diagnostic to 4 = excellent quality), vascular
attenuation, signal and contrast to noise ratio (SNR, CNR).
Patients were considered evaluable if no segment had a
score of 0.
Results Per-patient, the rate of fully evaluable CT scans
was 92.1, 95.4 and 94.6 % for iobitridol, iopromide and
iomeprol, respectively. Non-inferiority of iobitridol over
the best comparator was demonstrated with a 95 % CI
of the difference of [-8.8 to 2.1], with a pre-specified
non-inferiority margin of -10 %. Although average at-
tenuation increased with higher iodine concentrations,
average SNR and CNR did not differ between groups.
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Conclusions With current CT technology, iobitridol 350 mg
iodine/ml is not inferior to contrast media with higher iodine
concentrations in terms of image quality for coronary stenosis
assessment.
Key Points
• Iodine concentration is an important parameter for image
quality in coronary CTA.
• Contrast enhancement must be balanced against the amount
of iodine injected.
• Iobitridol 350 is non-inferior compared to CM with higher
iodine concentrations.
•Higher attenuation with higher iodine concentrations, but no
SNR or CNR differences.
Keywords Coronary computed tomography angiography .
Image quality . Contrast media . Iodine concentration . Safety
Introduction
Coronary computed tomography angiography (coronary
CTA) has become widely accepted in clinical practice [1–3].
Technology progress has increased the robustness and diag-
nostic performance of coronary CTA, resulting in improved
image quality and lower radiation exposure [4–9].
The protocols for administration of intravenous contrast me-
dia (CM) are of major importance in coronary CTA, usually
performed to identify coronary artery stenoses but also calcified
and non-calcified plaques [10–13]. The optimal intravascular
attenuation for coronary CT angiography is under debate [14,
15]. Several publications suggested that adequate opacification
of the vessel lumen for the simultaneous identification of both
calcified and non-calcified plaques requires a careful contrast
injection protocol that achieves a lumen opacification of at least
300 HU [15–17]. In principle, the Iodine Delivery Rate (IDR)
should be the reference when using different compounds for
intraluminal enhancement [18]. However, most centres do not
use this approach in clinical practice.
Higher iodine concentration of the injected CM is associated
with higher attenuation [16, 19]. However, increasing the total
amount of iodine injected could raise safety issues for patients
at risk such as contrast induced nephropathy [20–22].
Therefore, adequate contrast enhancement must be balanced
against the amount of iodine injected. Several studies have ad-
dressed the level of attenuation with different CM [14, 23, 24],
but few studies evaluated the impact of their concentration on
image quality [25]. Furthermore, whether differences less than
50 mg/ml of iodine concentration could affect image quality
remains to be clarified. The present study compared a CMwith
iodine concentration of 350 mg iodine/ml (iobitridol) to two
CM with higher iodine concentrations (iopromide 370 mg/ml
and iomeprol 400 mg/ml) for coronary CTA. The main objec-
tive of the study was to demonstrate the statistical non-
inferiority of iobitridol 350 compared to the best of the two
comparators in terms of image quality and interpretability as
measured by the rate of patients with CTscans evaluable for the
identification of coronary artery stenosis.
Material and methods
Study design and patient enrolment conditions
This study was a non-inferiority, multicentre, randomized,
double-blind, clinical trial on three parallel groups. Patients
were included in 23 centres from five countries between
November 2010 and September 2012 and randomized on a
1:1:1 ratio to undergo clinically indicated coronary CTA after
injection of iobitridol, iopromide or iomeprol. The study was
approved by each local ethics committees and the National
Health Authorities. Written informed consent was obtained
from each participating patient.
Symptomatic adult patients with suspected coronary artery
disease (CAD), and scheduled for coronary CT angiography
were enrolled in this study. Patients could not be included if
they had both a contraindication toβ-blocker medications and a
baseline heart rate above 65 beats per minute (bpm). Additional
reasons for exclusion were the presence of arrhythmias or non-
sinus rhythm, coronary artery bypass grafts or stents, artificial
heart valves, moderate to severe aortic valve stenosis, hyperthy-
roidism, clinical instability, severe renal failure or previous in-
jection of any CM within 48 hours prior to the study.
Patient preparation
β-blockers were mandatory if heart rate was >65 bpm. The
specific drug, dose and mode of administration were selected
according to site routine practice. A minimum dose of 0.8 mg
of sublingual nitroglycerine spray was mandatory immediate-
ly before the CT examination. Other pre-medication was per-
mitted, given according to operator preference, and recorded.
Injection of contrast media
For each patient, one of three CM was delivered intravenous-
ly: Iobitridol 350 mg iodine/ml (Xenetix®, Guerbet, Aulnay-
sous-Bois, France), iopromide 370 mg/ml (Ultravist®, Bayer
Healthcare, Berlin, Germany) and iomeprol 400 mg/ml
(Iomeron®, Bracco, Milan, Italy). Delivered volume and de-
livery rate of CM was consistent for the three CM but varied
according to patient body weight (BW): 60 ml injected at
4 ml/s for a BW <60 kg, 75 ml at 5 ml/s for a BW between
60 and 80 kg, 90 ml at 6 ml/s for a BW >80 kg. Therefore, the
iodine-delivery rate was lowest for iobitridol. CM was
warmed and injections were followed by a 100 % saline flush
of 75 ml administered at the same rate as the CM.
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Scan protocol
All coronary CTAs were performed on systems with at least 64
detector rows (single or dual source). The tube voltage was
adapted to the patient’s BW depending on the equipment used
in the site: either 120 kVp for all patients or 120 kVp for BW
≥80 kg and 100 kVp for BW<80 kg. Each patient first received
a non-contrast acquisition for the quantification of coronary
calcium, followed by a high-resolution contrast-enhanced ac-
quisition. Non-contrast scans were acquired according to local
protocol, mandating the use of 120 kV tube voltage and 3 mm
thickness of the reconstructed cross-sectional images.
Test bolus or bolus tracking [26, 27] as well as dose reduc-
tion techniques (e.g. mAs modulation, scan duration, tube
current and pitch) were chosen according to site specific rou-
tine. Retrospective ECG-gating was always allowed, whereas
prospectively ECG triggered data acquisition was only per-
mitted for patients with HR<65 bpm.
Dose length product (DLP) and volume CT dose index
(CTDIvol) were recorded for the non-enhanced and for the
contrast-enhanced coronary CTA acquisition.
Calcium scoring
The calcium score [13] was calculated on-site. Patients were then
classified using the following standard scale [28]: 1 = normal (no
calcium); 2 = mildly elevated (Agatston Score 1 to 100); 3 =
moderately elevated (Agatston Score 101 to 400); 4 = highly
elevated (Agatston Score 401 to 1000); 5 = severely elevated
(Agatston Score>1000).
Image reconstruction for coronary CTA
Cross-sectional image data sets were reconstructed using the
thinnest possible slice thickness and standard reconstruction
kernels (i.e. medium-smooth) without implementation of iter-
ative reconstruction algorithms in order to reduce software-
related attenuation variability. The choice of the best temporal
window was left to the local operators. Original axial DICOM
data were transferred for off-site reading purposes to a dedi-
cated image core laboratory.
Image evaluation for detection of stenosis
All CTA images were assessed by two independent, experi-
enced readers with more than 10 years of experience in coro-
nary CT angiography, both fully blinded to the patients´ clin-
ical characteristics and the CM used.
The primary endpoint was the rate of patients with evaluable
CT scans, i.e. CT scans that made it possible to identify or rule
out coronary artery stenoses in all segments of the coronary tree
with a reference diameter of 1.5 mm or more. Using a 5-point
scale, off-site readers graded the quality of all 18 segments of the
Society of Cardiovascular Computed Tomography (SCCT) cor-
onary segmentation model [29] (4 = excellent quality, full con-
fidence without any doubts concerning the presence/absence of
luminal stenosis; 3 = good quality, confidence concerning the
presence/absence of luminal stenosis; 2 = moderate quality, rel-
ative confidence, with minor doubts concerning the presence/
absence of luminal stenosis; 1 = poor quality, some doubts
concerning the presence/absence of stenosis; 0 = non diagnostic,
with relevant doubts concerning the presence/absence of steno-
sis). A patient’s CT scan was considered as evaluable for identi-
fication of coronary artery stenosis if none of the 18 coronary
segments had a score of 0 (except for segments graded 0 due to
an occlusion located proximally, which did not make the patient
non-evaluable).
As a secondary endpoint, a per-patient image quality score
was computed off-site by averaging segment quality scoreswith-
in patients.
Attenuation, signal and noise measurements
Arterial attenuation, signal-to-noise ratio (SNR) and contrast-
to-noise ratio (CNR) constituted secondary endpoints. Arterial
vascular attenuation was measured off-site as follows: one
region of interest (ROI) of 2 mm2 minimum size and located
in the lumen of the LAD, the LCX, the RCA and the LM
coronary artery; one ROI of 100 mm2 minimum size in the
ascending aorta and one ROI of 50 mm2 minimum size in the
left ventricle. Attenuation of LM, ascending aorta and left
ventricle was measured on pre and post contrast images.
The noise was measured in the aorta (100 mm2 minimum
size, located at the level of left main origin), air-filled cavities
(50 mm2 in bronchia or trachea) and muscle (25 mm2, thoracic
wall) in post-contrast images and was used to derive SNR and
CNR values.
Stenosis assessment and patient management
The presence of significant stenosis (>50 % of the lumen) in
the 18 SCCT segments was reported by on-site radiologists
using a 5-point scale (5 = certainly yes; 4 = probably yes; 3 =
doubtful; 2 = probably no ; 1 = certainly no).
On-site radiologists recorded the recommended manage-
ment from the following list: no action, medication, invasive
coronary angiography and other.
Coronary track rate
In order to determine whether image quality is sufficient for
automated segmentation as often used for evaluation, commer-
cially available software (“Comprehensive Cardiac Analysis” on
IntelliSpace Portal, Philips) was used to automatically track
LAD, LCX and RCA up to their distal segments and the number
of segments tracked per patient constituted the ‘coronary track
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rate’, which was assessed by a third independent off-site radiol-
ogist, also with more than 10 years of experience in cardiac CT.
Clinical safety
All adverse events (AEs), including cardiac events as evi-
denced by ECG (performed up to 10 min post-injection), were
reported from the patient’s signature of the informed consent
up to 30 min after the examination. The intensity of AEs was
classified on a 3-point scale, based on interference with daily
activities: mild (no interference), moderate (moderate interfer-
ence) or severe (the subject is unable to work). The causal
relationship of the AE to the CM injected was defined accord-
ing to the French Method of Causality Assessment [30].
Patient comfort and pain were assessed on-site using a self-
administered questionnaire (5-point scale ranging from 1
(worst situation) to 5 (best situation)) and a visual analogue
scale (VAS), respectively.
Statistical analysis
Assuming an expected proportion of 90 % of patients with
coronary CTAs evaluable for CAD diagnosis with the three
investigated contrast agents, 424 assessable patients (3x141)
were needed to ensure with 80 % power and 5 % two-sided
type-one error that the lower limit of the 95 % confidence
interval (95 % CI) of the difference between iobitridol 350
and the best of the two comparators (iopromide 370 or
iomeprol 400) is not greater than the clinical non-inferiority
margin set at -10 %.
Three patient populations were defined: all-included-
patients (AIP), full analysis set (FAS), and safety set.
AIP population included all patients enrolled in the
study and having signed the informed consent. FAS in-
cluded all patients who underwent the examination and
had available assessments of the primary endpoint for
iobitridol 350, iopromide 370 or iomeprol 400 examina-
tions. The safety set included all patients who had re-
ceived at least one injection of contrast agent, regardless
of the quantity.
For comparisons between the three groups, two-sided tests
were performed at a 5 % level of significance. In case of
multiple comparisons, significance level of each test was ad-
justed to ensure a 5 % overall significance level. Accuracy of
estimates was computed with 95 % CIs.
Student’s t-test and the F-test were used for quantitative
variables, whereas the Chi-square test was used for qualitative
variables.
Multiple regression models were performed to identify po-
tential relationship between calcium scoring and stenosis as-
sessment, image quality and territory.
Results
Study population
A total of 468 patients gave their consent and therefore were
included (58 %male; aged 57.8±12.4 years). Sixteen patients
were excluded: five patients did not have a CM injection, and
in 11 patients off-site image assessment was not possible due
to technical failures. Therefore, 452 patients were analysed in
the FAS and 463 in the safety set.
There were no significant differences between the
three groups in terms of demographics, clinical symp-
toms, risk factors and pre-CTA heart rate. No differ-
ences were noted in terms of requirement for β-
blockers for the CTA procedure, calcium score and ra-
diation dose (Table 1).
Image evaluation for detection of stenosis
The rate of patients with evaluable CT scans was not
significantly different between the three groups (92.1 %,
95.4 % and 94.6 % of patients in the FAS, for iobitridol,
iopromide and iomeprol, respectively) (Figure 1 and
Table 2). The 95 % CI of the difference between iobitridol
and the best of the two comparators (iopromide) was [-8.8
to 2.1], demonstrating the non-inferiority of iobitridol,
when compared to other CMs, in its ability to allow
CAD diagnosis through a complete assessment of coro-
nary artery segments.
The average score for image quality per-segment (total
number of segments=6,220) was 3.5±0.9, 3.5±0.8 and 3.4
±0.9 for the iobitridol, iopromide and iomeprol groups, re-
spectively (p>0.05).
Attenuation, signal and noise measurements
The average pre-contrast vascular attenuation calculated
from values of the ascending aorta, LM and left ventricle
was 42.2 ± 9.7 HU, without any difference between the
three groups (p = 0.993; Table 3). Vascular attenuation
was significantly increased in post-contrast images as
compared to pre-contrast images in all three structures.
Average post-contrast arterial vascular attenuation was
426.3 ± 92.9 HU, 449.8 ± 88.1 HU and 466.4 ± 104.6 HU
for the iobitridol, iopromide and iomeprol groups, respec-
tively (p =0.001).The difference between groups was sta-
tistically significant for absolute values; however, when
values accounting for noise were plotted as SNR and
CNR, differences were no longer significant (Table 3).
Measurements of noise in the ascending aorta showed
no significant difference between groups (p =0.311).
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Other secondary endpoints
No difference was observed regarding the number of significant
stenoses identified with the three CMs (p=0.580; Table 4).
Multivariate analyses showed a relationship between calci-
um scoring and stenosis assessment according to territory
(p<0.001) and between calcium scoring and image quality
regardless of the territory (p=0.007).
Table 1 Patients and procedure characteristics
Parameters Iobitridol 350 Iopromide 370 Iomeprol 400 Total Test
Demographics N= 155 N= 160 N= 153 N= 468
Age (years) 57.9 ± 12.2 58.7 ± 11.6 56.9 ± 13.4 57.8 ± 12.4 p = 0.457 (F)
Male gender 90 (58.1 %) 92 (57.5 %) 88 (57.5 %) 270 (57.7 %) p = 0.993 (C)
Height (cm) 170.4 ± 10.5 168.9 ± 8.9 169.8 ± 10.0 169.7 ± 9.8 p = 0.380 (F)
Body weight (kg) 78.7 ± 15.4 76.6 ± 16.9 77.3 ± 14.0 77.5 ± 15.5 p = 0.445 (F)
Body mass index (kg/m2) 27.0 ± 4.3 26.7 ± 4.7 26.7 ± 3.6 26.8 ± 4.2 p = 0.736 (F)
CV risk factors
Hypertension 79 (51.0 %) 84 (52.5 %) 82 (53.6 %) 245 (52.4 %) p = 0.898 (C)
Diabetes 15 (9.7 %) 17 (10.6 %) 17 (11.1 %) 49 (10.5 %) p = 0.916 (C)
Smoking 49 (31.6 %) 63 (39.4 %) 53 (34.6 %) 165 (35.3 %) p = 0.347 (C)
Family history of CAD 58 (37.4 %) 62 (38.8 %) 67 (43.8 %) 187 (40.0 %) p = 0.484 (C)
Hyperlipidaemia 65 (41.9 %) 68 (42.5 %) 64 (41.8 %) 197 (42.1 %) p = 0.992 (C)
History of obesity (BMI >30 kg/m2) 34 (21.9 %) 32 (20.0 %) 29 (19.0 %) 95 (20.3 %) p = 0.804 (C)
Symptoms at inclusion
Typical angina 41 (26.5 %) 40 (25.0 %) 36 (23.5 %) 117 (25.0 %) p = 0.839 (C)
Atypical angina 63 (40.6 %) 73 (45.6 %) 73 (47.7 %) 209 (44.7 %) p = 0.439 (C)
Non-angina chest pain 50 (32.3 %) 47 (29.4 %) 44 (28.8 %) 141 (30.1 %) p = 0.774 (C)
Calcium score N= 151 N= 152 N= 149 N= 452
Total score (mean ± SD; range) 154.0 ± 353.4
(0–2288)
204.8 ± 400.9
(0–1972)
135.6 ± 330.5
(0–1890)
165.0 ± 363.4
(0–2288)
p = 0.231(F)
In classes
Normal (no calcium) 65 (43.0 %) 70 (46.1 %) 72 (48.3 %) 207 (45.8 %) p = 0.631 (C)
Mild (1–100) 47 (31.1 %) 34 (22.4 %) 45 (30.2 %) 126 (27.9 %)
Moderate (101–400) 20 (13.2 %) 25 (16.4 %) 15 (10.1 %) 60 (13.3 %)
High (401–1,000) 11 (7.3 %) 13 (8.6 %) 10 (6.7 %) 34 (7.5 %)
Severe (>1000) 8 (5.3 %) 10 (6.6 %) 7 (4.7 %) 25 (5.5 %)
Heart rate N= 147 N= 156 N= 152 N= 455
Before CTA (bpm), mean ± SD (range) 61.6 ± 9.0
(45–113)
61.2 ± 9.1
(39–92)
62.0 ± 9.4
(37–90)
61.6 ± 9.2
(37–113)
p = 0.737(F)
During CTA (bpm), mean ± SD (range) 61.5 ± 9.7
(41–103)
61.0 ± 8.9
(40–89)
61.4 ± 10.4
(36–97)
61.3 ± 9.7
(36–103)
p = 0.893(F)
β-blockers N= 112 N= 111 N= 115 N= 338*
Intravenous 63 (56.3 %) 60 (54.1 %) 61 (53.0 %) 184 (54.4 %) p = 0.885 (C)
Oral 49 (43.8 %) 51 (45.9 %) 54 (47.0 %) 154 (45.6 %)
Radiation dose (post-injection values) N = 151 N= 152 N= 149 N= 452
Dose-length product mean ± SD; (range) 415.3 ± 312.3
(38.0–1360.0)
445.9 ± 323.0
(25.0–1562.0)
458.8 ± 307.1
(22.0–1437.0)
439.9 ± 314.1
(22.0–1562.0)
P = 0.469(F)
CT dose index mean± SD; (range) 26.5 ± 21.5
(0.0–101.0)
28.4 ± 20.7
(1.0–101.0)
30.0 ± 21.4
(1.0–96.0)
28.3 ± 21.2
(0.0–101.0)
P = 0.373(F)
Results are expressed as mean ± standard deviation or n ( %) of patients
* Subgroup of patients who received β-blockers as premedication for CTA
BMI body mass index, CAD coronary artery disease, CV cardiovascular, CT computed tomography, CTA CTangiography, F F-test, C Chi-square test
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Amean of 11 segments were automatically tracked out of a
maximum of 13 segments per patient whatever the contrast
media injected (Table 4).
The mean score for comfort of the examination rated by the
patient was good (4.4±0.6) and similar for all three groups.
Patient comfort was confirmed by a low reported intensity of
pain (mean score of less than 1 out of 10 cm on VAS for the
three groups).
Regarding patient management, no action was required af-
ter the CTA for 73 % of the patients overall, with no signifi-
cant difference between groups.
Clinical safety
The percentage of patients experiencing post CM-injection AEs
was 15.1%; 19.5% and 15.1%, for the iobitridol, iopromide and
iomeprol groups, respectively (Table 5). Most AEs concerned
cardiac disorders, which were reported through systematic
ECG follow-up performed up to 10 min post-injection. Overall,
mean heart rate was 65.0±9.7 bpm 2min after CM injection and
62.8±9.3 bpm 10 min after CM injection, and was similar in all
three groups.
No severe AEs were reported. Only mild events were re-
ported with iobitridol while four and seven moderate events
were reported with iopromide and iomeprol, respectively. Few
post-CM AEs were considered possibly related to CM admin-
istration: two in the iobitridol group and five in the iopromide
group as well as in the iomeprol group. The cardiac events
considered possibly related to CM injection were bradycardia
(one patient in each group) and extrasystoles (two patients in
the iomeprol group). Other possibly related events were pain
in the iobitridol group, injection site pain, nausea, headache
and urticaria in the iopromide group, injection site pain and
feeling hot in the iomeprol group.
Discussion
The rationale for this trial was that CM iodine concentration
may not play a role in the ability to visualize coronary stenoses
by CTA. This study demonstrated the non-inferiority of
iobitridol 350 in providing evaluable CT scans for assessment
of coronary stenosis, as compared to CM with higher iodine
concentrations (iopromide 370 mg iodine/ml and iomeprol
400 mg iodine/ml). These two CMs had been compared in a
previous study without differences in terms of image quality
[25]. Our study, the largest so far to address the relationship
between iodine concentration and image quality, indicates the
possibility of further reducing iodine content. Reflecting cur-
rent clinical practice in many sites, IDR was not adjusted
according to the iodine concentration of each CM.
Our results are in line with previous studies in which higher
iodine concentrations were associated with higher intravascu-
lar attenuation [14, 31–34]. However, comparison is difficult
since the volume of iodine injected was not always adjusted to
patient weight [14]. The fact that no difference was observed
between CMs when considering SNR and CNR cannot be
fully explained. Compared to previous studies, image noise
was relatively low given the advanced technology of the
CT systems that were used. This limits the influence of
noise. Also, statistically, variations in image noise across
patients and systems may have been larger than variations
in contrast enhancement, so that lack of significance re-
garding the difference between the three patient groups
may be a statistical effect.
Recent improvements in terms of radiation dose manage-
ment also affect vascular attenuation and noise. For instance,
lower kV protocols (80 kV) can now be used for patients with
small body mass indices (BMIs) allowing for a reduction in
radiation dose while increasing vascular attenuation [6]. In
this study, no protocol using less than 100 kV was performed.
Another recent development affecting noise is related to the
Fig. 1 Transaxial cross-sections (0.6-mm slice width) and curved
multiplanar reconstructions of the right coronary artery, all displayed at
a window level of 1,200 and width of 200 HU. (a, b) Investigation
performed using iobitridol 350 mg/ml. (c, d) Investigation performed
using iopromide 370 mg/ml. (e, f) Investigation performed using
iomeprol 400 mg/ml. LA left atrium, LV left ventricle, RA right atrium,
RV= right ventricle
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Table 2 Image quality per patient – off-site evaluation (FAS, N= 452)
Iobitridol 350 Iopromide 370 Iomeprol 400 All Test
Patient level N = 151 N= 152 N=149 N= 452
Patients with evaluable CT scans 139 (92.1 %) 145 (95.4 %) 141 (94.6 %) 425 (94.0 %) p = 0.438 (C)
Number of non–diagnostic segments/patient
0 139 (92.1 %) 145 (95.4 %) 141 (94.6 %) 425 (94.0 %) p = 0.181 (C)
1–5 5 (3.3 %) 3 (2.0 %) 1 (0.7 %) 9 (2.0 %)
6–10 4 (2.6 %) 3 (2.0 %) 4 (2.7 %) 11 (2.4 %)
>10 3 (2.0 %) 1 (0.7 %) 3 (2.0 %) 7 (1.5 %)
Average image quality mean ± SD; (range) 3.5 ± 0.9 (0.0–4.0) 3.5 ± 0.8 (0.2–4.0) 3.4 ± 0.9 (0.0–4.0) 3.5 ± 0.9 (0.0–4.0) p = 0.750 (F)
Segment level N = 2082 N= 2090 N=2048 N= 6220
Image quality
0 – Non diagnostic 89 (4.3 %) 43 (2.1 %) 71 (3.5 %) 203 (3.3 %)
1 – Poor quality 65 (3.1 %) 82 (3.9 %) 61 (3.0 %) 208 (3.3 %)
2 – Moderate quality 143 (6.9 %) 151 (7.2 %) 187 (9.1 %) 481 (7.7 %)
3 – Good quality 258 (12.4 %) 313 (15.0 %) 334 (16.3 %) 905 (14.5 %)
4 – Excellent quality 1527 (73.3 %) 1501 (71.8 %) 1395 (68.1 %) 4423 (71.1 %)
F F–test; C Chi–square test
Table 3 Signal quantification at patient level - off-site evaluation (FAS, N= 452)
Iobitridol 350 Iopromide 370 Iomeprol 400 All p-value
(F-Test)N= 151 N= 152 N= 149 N= 452
Attenuation
Ascending aorta
Pre 44.8 ± 9.9 44.2 ± 10.3 44.7 ± 11.3 44.6 ± 10.5 0.864
Post 440.0 ± 94.0 465.0 ± 93.6 476.8 ± 114.9 460.6 ± 102.2 0.006
Left ventricle
Pre 42.0 ± 11.6 41.1 ± 10.7 41.4 ± 11.1 41.5 ± 11.1 0.789
Post 382.3 ± 108.8 401.2 ± 113.7 431.1 ± 124.3 404.7 ± 117.2 0.001
Left main coronary artery
Pre 39.7 ± 14.5 41.1 ± 15.7 40.8 ± 13.4 40.5 ± 14.6 0.666
Post 441.9 ± 101.0 466.8 ± 100.8 479.9 ± 116.6 462.8 ± 107.2 0.008
Average pre-contrast 42.2 ± 9.7
(21.1–90.5)
42.2 ± 10.2
(15.3–92.0)
42.3 ± 9.4
(19.9–84.6)
42.2 ± 9.8
(15.3–92.0)
0.993
Average post-contrast 426.3 ± 92.9
(240.6–726.2)
449.8 ± 88.1
(240.3–717.4)
466.4 ± 104.6
(185.5–766.9)
447.4 ± 96.6
(185.5–766.9)
0.001
Average noise aorta 32.5 ± 10.5
(15.5–80.5)
32.8 ± 10.0
(13.8–69.2)
34.3 ± 11.5
(14.3–75.7)
33.2 ± 10.7
(13.8–80.5)
0.311
Average SNR 16.2 ± 5.6
[7.0–45.7)
17.1 ± 5.0
(6.5–31.4)
17.6 ± 6.6
(5.2–46.4)
17.0 ± 5.8
(5.2–46.4)
0.109
Average CNR 14.4 ± 5.4
(5.6–42.8)
15.3 ± 4.8
(5.8–28.7)
15.8 ± 6.5
(4.3–48.0)
15.2 ± 5.6
(4.3–48.0)
0.090
All values are expressed as Hounsfield Units (HU) with mean and standard deviation. The range is provided in brackets for average values.
FAS full analysis set, CNR contrast to noise ratio, SNR signal to noise ratio, Pre prior to contrast media intravenous administration, Post after contrast
media intravenous administration, SD standard deviation
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Table 4 Secondary efficacy endpoints
Secondary endpoints Iobitridol 350 Iopromide 370 Iomeprol 400 Total Test
Pain assessment N =148 N =148 N =144 N=440
Pain during and after
examination - VAS (cm)
0.4 ± 0.9 0.5 ± 1.0 0.7 ± 1.5 0.6 ± 1.2 p = 0.049 (F)
Patient comfort N = 150 N= 151 N= 148 N=449
Comfort score* 4.4 ± 0.6 4.4 ± 0.6 4.3 ± 0.6 4.4 ± 0.6 p = 0.347 (F)
Patient management N= 151 N= 152 N= 149 N=452
No action 107 (70.9 %) 109 (71.7 %) 114 (76.5 %) 330 (73.0 %) p = 0.494 (C)
Medication 22 (14.6 %) 24 (15.8 %) 19 (12.8 %) 65 (14.4 %) p = 0.752 (C)
Invasive coronary angiography 20 (13.2 %) 18 (11.8 %) 14 (9.4 %) 52 (11.5 %) p = 0.572 (C)
Other recommendation 6 (4.0 %) 6 (3.9 %) 8 (5.4 %) 20 (4.4 %) p = 0.791 (C)
Stenosis (>50 %) assessment
Per-segment N= 2718 N= 2736 N= 2682 N=8136 p = 0.003 (C)
Certainly no 1670 (84.3 %) 1729 (83.4 %) 1753 (86.5 %) 5152 (84.8 %)
Probably no 235 (11.9 %) 263 (12.7 %) 211 (10.4 %) 709 (11.7 %)
Doubtful 26 (1.3 %) 32 (1.5 %) 26 (1.3 %) 84 (1.4 %)
Probably yes 29 (1.5 %) 17 (0.8 %) 28 (1.4 %) 74 (1.2 %)
Certainly yes 20 (1.0 %) 31 (1.5 %) 8 (0.4 %) 59 (1.0 %)
Per patient N =151 N= 152 N= 149 N=452
overall significant stenosis
(doubtful to certainly)
31 (20.5 %) 30 (19.7 %) 24 (16.1 %) 85 (18.8 %) p = 0.580 (C)
Coronary track rate N= 151 N= 152 N= 149 N=452
number of tracked
segments per patient
10.9 ± 2.2 10.8 ± 2.4 11.1 ± 2.3 10.9 ± 2.3
Results are expressed as mean ± standard deviation or n (%) of patients or segments
VAS visual analogue scale (10 cm), F F–test; C Chi–square test
*Comfort during examination was rated by the patient on a scale from 1 (very poor) to 5 (very good)
Table 5 Incidence and
characteristics of adverse events
(safety set, N = 463)
Adverse events Iobitridol 350 Iopromide 370 Iomeprol 400 All
N = 152 N= 159 N= 152 N= 463
n ( %) of patients with at least one:
Pre CM-injection AE 24 (15.8 %) 14 (8.8 %) 15 (9.9 %) 53 (11.4 %)
Post CM-injection AE 23 (15.1 %) 31 (19.5 %) 23 (15.1 %) 77 (16.6 %)
Number of post CM-injection AE 26 36 28 90
Intensity
Mild 26 (100.0 %) 32 (88.9 %) 20 (71.4 %) 78 (86.7 %)
Moderate 0 (0.0 %) 4 (11.1 %) 7 (25.0 %) 11 (12.2 %)
Severe 0 (0.0 %) 0 (0.0 %) 1 (3.6 %) 1 (1.1 %)
Outcome
Resolved 26 (100.0 %) 34 (94.4 %) 27 (96.4 %) 87 (96.7 %)
Ongoing 0 (0.0 %) 2 (5.6 %) 1 (3.6 %) 3 (3.3 %)
Relationship to CM
Not related 12 (46.2 %) 22 (61.1 %) 18 (64.3 %) 52 (57.8 %)
Doubtfully related 12 (46.2 %) 9 (25.0 %) 5 (17.9 %) 26 (28.9 %)
Possibly related 2 (7.7 %) 5 (13.9 %) 5 (17.9 %) 12 (13.3 %)
AE adverse events, CM contrast media
One patient could have experienced several adverse events
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introduction of iterative reconstruction algorithms which are
able to significantly reduce image noise thus improving SNR
and CNR while keeping intravascular attenuation constant [6,
9]. It is therefore reasonable to expect that using lower kV
settings and an iterative reconstruction algorithm may have
yielded better SNR values regardless of other parameters.
However, the inclusion of iterative reconstruction algorithms
might have hampered comparisons to images from other scan-
ners unless image noise would have been adapted by lowering
the radiation exposure during the acquisition. Finally, newer
detectors have been introduced with increased efficiency and
lower noise [5] hence promoting the use of less iodine content
(less volume or lower concentrations [35–40]).
Regarding safety, iobitridol use was associated with the
lowest incidence of related AEs (i.e. 1.3 % corresponding to
two patients), confirming the excellent safety profile of this
CM [41–43].
Study limitations
The main limitation of the study is the absence of a gold
standard such as conventional angiography. Diagnostic ac-
curacy could therefore not be compared between groups. A
similar number of scans positive for stenosis in all three
groups, however, indicate that there is likely no systematic
difference in stenosis detection rates between the three
CMs.
Another limitation is the relatively low coronary calci-
um burden. This is typical for the target population of the
study. While severely calcified vessels may benefit from
increased vessel lumen opacification for reliable evaluation
[16, 17], this was not specifically evaluated and the ability
to identify calcified lesions was not compared across the
three CMs. A systematic assessment of renal function post-
contrast was not performed. Further, contrast injection
rates for the three CMs used were constant and not adjusted
to achieve equal IDR across the three groups. Hence IDR
ranged from 1,400 to 1,600 mg iodine/s in the patients with
the lowest body weight and from 2,100 to 2,400 mg iodine/
s in patients with the highest body weight. This reflects
clinical practice, where protocols typically prescribe injec-
tion rates in ml/s and not IDR, and explains why higher
attenuation values were observed for higher concentration
CMs, but did not lead to significant differences regarding
SNR, CNR or the clinical rating of image quality.
Conclusion
With current CT technology, iobitridol 350 mg iodine/ml is
not inferior to CMs with higher iodine in terms of image
quality for coronary stenosis assessment by CTA. When con-
sidering image quality, SNR and CNR, iobitridol yielded
similar values to iopromide and iomeprol. Iobitridol, with a
lower content of iodine, holds the potential to reduce the risk
of adverse reactions, as supported by its excellent safety pro-
file. It is likely that developments in image reconstruction and
detector technology may further allow improving image qual-
ity while minimizing the necessary amount of injected iodine.
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